1. Barnett SK, Armas-Kolostroubis L, Sension M, Riedel DJ, et al.
   Cabotegravir-rilpivirine treatment initiation in a nonvirologically suppressed patient.
   AIDS 2022;36:1475-1476.
   


2. Phillips AN, Sibanda E, Sikwese K, Bansi-Matharu L, et al.
   Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa.
   AIDS 2022;36:1473-1475.
   


3. Carrasco I, Olveira A, Lancharro A, Escosa L, et al.
   Fatty liver disease in children living with HIV: a ghostly iceberg.
   AIDS 2022;36:1471-1472.
   


4. Sebastiani G, Sebastiani G.
   Fatty liver in children with HIV: a clinical iceberg?
   AIDS 2022;36:1469-1471.
   


5. Chammartin F, Kusejko K, Pasin C, Trkola A, et al.
   Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
   AIDS 2022;36:1465-1468.
   


6. Lurain K, Uldrick TS, Navarro JT.
   Leveraging fine-needle aspiration to improve HIV-associated lymphoma diagnostic capacity in resource-limited settings.
   AIDS 2022;36:1461-1463.
   


7. Stapleton JT, Bedimo RJ, Guaraldi G.
   Switch back from TAF to TDF or rather switch forward from metabolic toxicities of drugs to metabolic health of people living with HIV.
   AIDS 2022;36:1457-1459.
   


8. Schneider JA, Bouris A.
   Ryan White programming that primarily supports clinical care falls short when core people needs are not met: further evidence from the medical monitoring project.
   AIDS 2022;36:1453-1456.
   


9. Wood BR, Stekler JD.
   Baseline HIV genotype drug resistance testing: is it time for more or less?
   AIDS 2022;36:1449-1451.
   


10. Lesko CR, Edwards JK, Hanna DB, Mayor AM, et al.
    Longitudinal HIV care outcomes by gender identity in the United States.
    AIDS 2022.
    


11. Yazdani K, Salters K, Shen T, Dolguikh K, et al.
    A twenty-year population-based study of all-cause and cause-specific mortality among people with concurrent HIV and psychotic disorders.
    AIDS 2022.
    


12. Mann LM, Le Guillou A, Goodreau SM, Marcus JL, et al.
    Correlations between community-level HIV preexposure prophylaxis coverage and individual-level sexual behaviors among US men who have sex with men.
    AIDS 2022.
    


13. Pala AN, Kempf MC, Konkle-Parker D, Wilson TE, et al.
    Intersectional stigmas are associated with lower viral suppression Rates and ART adherence among Women living with HIV.
    AIDS 2022.
    


14. Fitch KV, Mccallum SA, Erlandson KM, Overton ET, et al.
    Diet in a global cohort of adults with HIV at Low to Moderate Traditional Cardiovascular Disease Risk.
    AIDS 2022.
    


15. Kauppinen KJ, Aho I, Sutinen J.
    Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
    AIDS 2022.
    


16. Bui HTM, Adamson PC, Le GM, Klausner JD, et al.
    Pharyngeal Chlamydia trachomatis in Men Who Have Sex With Men in an HIV Pre-Exposure Prophylaxis Program in Hanoi, Vietnam.
    Clin Infect Dis 2022.
    


17. Chaplin B, Agbaji O, Nieva HR, Olatunde B, et al.
    The Timeliness of Point of Care Viral Load Results Improves HIV Monitoring in Nigeria.
    Clin Infect Dis 2022.
    


18. Wei F, Goodman MT, Xia N, Zhang J, et al.
    Incidence and clearance of anal human papillomavirus infection in 16 164 individuals, according to HIV status, gender, and male sexuality: an international pooled analysis of 34 longitudinal studies.
    Clin Infect Dis 2022.
    


19. Babalola CM, Siebert JC, Kallapur SG, Maecker HT, et al.
    Discrete Plasma Cytokine Profiles among Pregnant Women in Botswana by Chlamydia trachomatis infection, HIV status, and Gestational age.
    J Infect Dis 2022.
    


20. Rupasinghe D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al.
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol 2022.
    


21. Rudicell RS, Piel AK, Stewart F, Moore DL, et al.
    Correction for Rudicell et al., "High Prevalence of Simian Immunodeficiency Virus Infection in a Community of Savanna Chimpanzees".
    J Virol 2022.
    


22. Lin J, Law R, Korosec CS, Zhou C, et al.
    Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
    J Virol 2022.
    


23. Mayer KH, Phanuphak N, Mgodi N, Grinsztejn B, et al.
    New HIV prevention approaches: promise, praxis, and pitfalls.
    Lancet 2022;400:257-259.
    


24. Bekker LG.
    Long-acting agents for HIV treatment and prevention.
    Nat Med 2022.
    


25. Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, et al.
    Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series.
    BMJ 2022;378:e072410.
    

Display articles in

• Abstract format
• Medline format